Clinical ObservationsThe Impact of DEFLAZACORT (cas 13649-88-2) on Puberty in Duchenne Muscular Dystrophy
-
Add time:09/05/2019 Source:sciencedirect.com
BackgroundThe routine use of glucocorticoids has increased the longevity of patients with Duchenne muscular dystrophy. Long-term steroid therapy may have adverse effects on endocrine function and could influence the onset of puberty.
We also recommend Trading Suppliers and Manufacturers of DEFLAZACORT (cas 13649-88-2). Pls Click Website Link as below: cas 13649-88-2 suppliers
Prev:Binding of the anti-inflammatory steroid deflazacort to glucocorticoid receptors in brain and peripheral tissues. In vivo and in vitro studies
Next:Determination of the solubility, dissolution enthalpy and entropy of DEFLAZACORT (cas 13649-88-2) in different solvents) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Case reportTwo siblings with limb-girdle muscular dystrophy type 2E responsive to DEFLAZACORT (cas 13649-88-2)09/26/2019
- Case ReportToxic epidermal necrolysis associated with DEFLAZACORT (cas 13649-88-2) therapy with nephrotic syndrome09/25/2019
- A comparative study of hydrocortisone versus DEFLAZACORT (cas 13649-88-2) in drug-resistant epilepsy of childhood09/24/2019
- Identification of plasma interleukins as biomarkers for DEFLAZACORT (cas 13649-88-2) and omega-3 based Duchenne muscular dystrophy therapy09/10/2019
- Original ArticleDEFLAZACORT (cas 13649-88-2) alleviate pro-inflammatory cytokines expression, oxidative stress and histopathological alterations in collagen induced arthritis in Wistar rats09/09/2019
- Short communicationIsolation and structural characterization of novel photolytic degradation impurities of DEFLAZACORT (cas 13649-88-2) using Q-TOF, 2D-NMR and FTIR09/08/2019
- DEFLAZACORT (cas 13649-88-2)09/07/2019
- Determination of the solubility, dissolution enthalpy and entropy of DEFLAZACORT (cas 13649-88-2) in different solvents09/06/2019
